Objective: To explore the clinical effect and safety of rebamipiden in treating chronic erosive gastritis. Method: 80 patients with chronic erosive gastritis were randomly divided into the intervention group (40 cases) and control group (40 cases). The intervention group were treated with rebamipide oral, the control group were treated with sucralfate oral, both groups were treated for 8 successive weeks. The symptoms were assessed before and 1,4,8 weeks after the treatment. Gastroscopic and gastric mucosal his-topathologic examination and score were applied before and after the treatment. Result: The patients symptom scores, endoscopy scores was better than the control group, the difference was statistically significant (P ＜0.05). Conclusion: The rebamipide in treating chronic erosive gastritis is more effective and safely, and hence is worthy of applying in clinical practice.%目的:探讨瑞巴派特治疗慢性糜烂性胃炎的临床疗效和安全性.方法:将80例慢性糜烂性胃炎患者随机分成观察组和对照组,每组各40例,观察组口服瑞巴派特,对照组口服硫糖铝,疗程8周.治疗前及治疗1、4、8周对患者进行症状评分,治疗前、后分别行胃镜检查及胃黏膜组织病理学检查和评分.结果:观察组患者症状评分、胃镜评分好于对照组,差异有统计学意义(P＜0.05).结论:瑞巴派特治疗慢性糜烂性胃炎安全有效,值得临床推广应用.
展开▼
